Supramolecular Coordination Platforms for Smart Theranostics: Leveraging the Dynamic Molecular Networks of Metal–Polyphenol Assemblies
DOI: https://doi.org/10.1002/agt2.70394
DOI: https://doi.org/10.1002/agt2.70394
November 8, 2026 at 12:30 PM
Supramolecular Coordination Platforms for Smart Theranostics: Leveraging the Dynamic Molecular Networks of Metal–Polyphenol Assemblies
DOI: https://doi.org/10.1002/agt2.70394
DOI: https://doi.org/10.1002/agt2.70394
"Very exciting to see Lutetium moving earlier in treatment of prostate cancer patients"
#L177
#Theranostics
#L177
#Theranostics
November 4, 2026 at 8:15 PM
"Very exciting to see Lutetium moving earlier in treatment of prostate cancer patients"
#L177
#Theranostics
#L177
#Theranostics
Telix Joins Forces with Thera4Care to Advance Next-Gen Theranostics for Cancer Treatment#Australia#Melbourne#Telix_Pharmaceuticals#Thera4Care#TLX400-Tx
Telix Joins Forces with Thera4Care to Advance Next-Gen Theranostics for Cancer Treatment
Telix Pharmaceuticals has partnered with Thera4Care to enhance access to innovative cancer theranostics in Europe through their new collaboration initiative.
third-news.com
November 5, 2026 at 5:53 AM
Telix Joins Forces with Thera4Care to Advance Next-Gen Theranostics for Cancer Treatment#Australia#Melbourne#Telix_Pharmaceuticals#Thera4Care#TLX400-Tx
The company said it raised over $10 million in Q3 to support the trial of the flourine-18-labeled agent, which will enroll about 280 patients with suspected brain metastases.
FDA Clears Radiopharm Theranostics’ Phase III Brain Mets Imaging Trial Plan
FDA Clears Radiopharm Theranostics’ Phase III Brain Mets Imaging Trial Plan
ebx.sh
November 4, 2026 at 11:52 PM
The company said it raised over $10 million in Q3 to support the trial of the flourine-18-labeled agent, which will enroll about 280 patients with suspected brain metastases.
#RADX Radiopharm Theranostics Reports Business Update
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-reports-business-dc95jlcuaxa6.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-reports-business-dc95jlcuaxa6.html?utm_source=stocktitan-bluesky&utm_medium=social
www.stocktitan.net
November 2, 2026 at 1:00 PM
#RADX Radiopharm Theranostics Reports Business Update
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-reports-business-dc95jlcuaxa6.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-reports-business-dc95jlcuaxa6.html?utm_source=stocktitan-bluesky&utm_medium=social
#RADX Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain…
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-announces-alignment-with-u-s-fda-on-single-87x4w3w2nkfg.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-announces-alignment-with-u-s-fda-on-single-87x4w3w2nkfg.html?utm_source=stocktitan-bluesky&utm_medium=social
Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 4, 2026 at 12:00 PM
#RADX Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain…
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-announces-alignment-with-u-s-fda-on-single-87x4w3w2nkfg.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-announces-alignment-with-u-s-fda-on-single-87x4w3w2nkfg.html?utm_source=stocktitan-bluesky&utm_medium=social
📊 Maravai LifeSciences published Q3 earnings presentation.
🤝 Telix joined Thera4Care with TLX400-Tx for theranostics.
📊 Lumen Technologies published Q3 earnings presentation.
📉 Shoals merged with Array in an all-stock $1.23B deal.
🤝 Telix joined Thera4Care with TLX400-Tx for theranostics.
📊 Lumen Technologies published Q3 earnings presentation.
📉 Shoals merged with Array in an all-stock $1.23B deal.
November 5, 2026 at 6:32 AM
📊 Maravai LifeSciences published Q3 earnings presentation.
🤝 Telix joined Thera4Care with TLX400-Tx for theranostics.
📊 Lumen Technologies published Q3 earnings presentation.
📉 Shoals merged with Array in an all-stock $1.23B deal.
🤝 Telix joined Thera4Care with TLX400-Tx for theranostics.
📊 Lumen Technologies published Q3 earnings presentation.
📉 Shoals merged with Array in an all-stock $1.23B deal.
#MOLN Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026
https://www.stocktitan.net/news/MOLN/molecular-partners-to-present-on-dll3-targeting-radio-dar-pin-mp0712-ivuzgmyyjgtn.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MOLN/molecular-partners-to-present-on-dll3-targeting-radio-dar-pin-mp0712-ivuzgmyyjgtn.html?utm_source=stocktitan-bluesky&utm_medium=social
Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026
Molecular Partners (MOLN) will present on its cancer treatment candidate MP0712 at scientific conferences on November 7 and December 5, 2026. Co-developed with Orano Med, MP0712 targets DLL3, a protein expressed by certain tumors.The November 7 oral presentation at the SNMMI Theranostics Conference in Bethesda will discuss target expression and advancing MP0712 into clinical testing. The December 5 poster at the North America Conference on Lung Cancer in Scottsdale will cover initial dose-escalation data from a first-in-human Phase 1/2a study in patients with small cell lung cancer and other DLL3-expressing solid tumors. Presentations will be available on the company website afterward.
www.stocktitan.net
November 5, 2026 at 6:00 AM
#MOLN Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026
https://www.stocktitan.net/news/MOLN/molecular-partners-to-present-on-dll3-targeting-radio-dar-pin-mp0712-ivuzgmyyjgtn.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MOLN/molecular-partners-to-present-on-dll3-targeting-radio-dar-pin-mp0712-ivuzgmyyjgtn.html?utm_source=stocktitan-bluesky&utm_medium=social
Theranostics market: $3.60B in 2025 to $12.01B by 2035, a 12.8% CAGR. Radioligand therapy approvals lead growth, North America holds 45% share. www.strategicrevenueinsights.com/industry/th... #MarketResearch
November 2, 2026 at 3:30 AM
Theranostics market: $3.60B in 2025 to $12.01B by 2035, a 12.8% CAGR. Radioligand therapy approvals lead growth, North America holds 45% share. www.strategicrevenueinsights.com/industry/th... #MarketResearch
Kicking off our first UCSF Radiation Oncology & @ucsfimaging.bsky.social Radiology Joint Research Symposium! Theranostics, Physics, Radiobiology
October 30, 2026 at 3:55 PM
Kicking off our first UCSF Radiation Oncology & @ucsfimaging.bsky.social Radiology Joint Research Symposium! Theranostics, Physics, Radiobiology
Theranostics Market Size, Share, Type, Trends, Report 2035 www.marketresearchfuture.com/reports/ther...
Theranostics Market Size, Share, Type, Trends, Report 2035
Theranostics Market growth is projected to reach 31.21 USD billion, at a 11.77% CAGR by driving industry size, share, top company analysis, segments research, trends and forecast report 2025 to 2035.
www.marketresearchfuture.com
October 30, 2026 at 7:52 AM
Theranostics Market Size, Share, Type, Trends, Report 2035 www.marketresearchfuture.com/reports/ther...
📑 Dual-Imaging Nanoparticles for Cancer
👉 mdpi.com/3780596
Gelatin-coated Gd₂O₃ nanoparticles combined enzyme-responsive doxorubicin release with MRI and photoacoustic imaging, suppressing tumor growth in mice.
#Theranostics #Nanomaterials
👉 mdpi.com/3780596
Gelatin-coated Gd₂O₃ nanoparticles combined enzyme-responsive doxorubicin release with MRI and photoacoustic imaging, suppressing tumor growth in mice.
#Theranostics #Nanomaterials
November 2, 2026 at 4:52 AM
📑 Dual-Imaging Nanoparticles for Cancer
👉 mdpi.com/3780596
Gelatin-coated Gd₂O₃ nanoparticles combined enzyme-responsive doxorubicin release with MRI and photoacoustic imaging, suppressing tumor growth in mice.
#Theranostics #Nanomaterials
👉 mdpi.com/3780596
Gelatin-coated Gd₂O₃ nanoparticles combined enzyme-responsive doxorubicin release with MRI and photoacoustic imaging, suppressing tumor growth in mice.
#Theranostics #Nanomaterials
$RDPTF 🏥
Radiopharm Theranostics reported positive Phase 1 imaging data for RAD301 supporting advancement toward Phase 2 development in pancreatic ductal adenocarcinoma.
Selected from hundreds of headlines
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
Radiopharm Theranostics reported positive Phase 1 imaging data for RAD301 supporting advancement toward Phase 2 development in pancreatic ductal adenocarcinoma.
Selected from hundreds of headlines
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
November 2, 2026 at 1:03 PM
$RDPTF 🏥
Radiopharm Theranostics reported positive Phase 1 imaging data for RAD301 supporting advancement toward Phase 2 development in pancreatic ductal adenocarcinoma.
Selected from hundreds of headlines
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
Radiopharm Theranostics reported positive Phase 1 imaging data for RAD301 supporting advancement toward Phase 2 development in pancreatic ductal adenocarcinoma.
Selected from hundreds of headlines
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
VERITON-CT 400 All-Energy by Spectrum Dynamics
https://www.byteseu.com/2494070/
VERITON-CT 400 All-Energy The VERITON-CT 400 All-Energy redefines what is possible with SPECT/CT. Built for the theranostics era, this 360-degree digital CZT platform brings diagnostic and therapeutic isotope …
https://www.byteseu.com/2494070/
VERITON-CT 400 All-Energy The VERITON-CT 400 All-Energy redefines what is possible with SPECT/CT. Built for the theranostics era, this 360-degree digital CZT platform brings diagnostic and therapeutic isotope …
VERITON-CT 400 All-Energy by Spectrum Dynamics - Bytes Europe
VERITON-CT 400 All-Energy
www.byteseu.com
November 3, 2026 at 5:39 AM
VERITON-CT 400 All-Energy by Spectrum Dynamics
https://www.byteseu.com/2494070/
VERITON-CT 400 All-Energy The VERITON-CT 400 All-Energy redefines what is possible with SPECT/CT. Built for the theranostics era, this 360-degree digital CZT platform brings diagnostic and therapeutic isotope …
https://www.byteseu.com/2494070/
VERITON-CT 400 All-Energy The VERITON-CT 400 All-Energy redefines what is possible with SPECT/CT. Built for the theranostics era, this 360-degree digital CZT platform brings diagnostic and therapeutic isotope …
🚨 #REVIEW 🚨
Sofias et al. discuss recent advances in radiotheranostic strategies, advances in nanotheranostic and microtheranostic platforms, and image-guided therapeutic and surgical interventions in oncology.
📖 👇
Sofias et al. discuss recent advances in radiotheranostic strategies, advances in nanotheranostic and microtheranostic platforms, and image-guided therapeutic and surgical interventions in oncology.
📖 👇
Cancer theranostics - Nature Reviews Cancer
Theranostics integrates diagnostic imaging with targeted therapy to enhance cancer treatment. In this Review, Sofias et al. discuss recent advances in radiotheranostic strategies, advances in nanotheranostic and microtheranostic platforms, and image-guided therapeutic and surgical interventions in oncology.
dlvr.it
October 30, 2026 at 5:23 PM
🚨 #REVIEW 🚨
Sofias et al. discuss recent advances in radiotheranostic strategies, advances in nanotheranostic and microtheranostic platforms, and image-guided therapeutic and surgical interventions in oncology.
📖 👇
Sofias et al. discuss recent advances in radiotheranostic strategies, advances in nanotheranostic and microtheranostic platforms, and image-guided therapeutic and surgical interventions in oncology.
📖 👇
Theranostics Market Size, Share, Type, Trends, Report 2035 www.marketresearchfuture.com/reports/ther...
Theranostics Market Size, Share, Type, Trends, Report 2035
Theranostics Market growth is projected to reach 31.21 USD billion, at a 11.77% CAGR by driving industry size, share, top company analysis, segments research, trends and forecast report 2025 to 2035.
www.marketresearchfuture.com
October 30, 2026 at 7:52 AM
Theranostics Market Size, Share, Type, Trends, Report 2035 www.marketresearchfuture.com/reports/ther...
The authors included RRIDs in their in Theranostics paper! RRIDs improve reproducibility in scientific research. #OpenScience #STMpublishing #ReproducibleResearch
Neuronal mitochondrial disaggregase CLPB ameliorates Huntington's disease pathology in mice
Read the full paper: Neuronal mitochondrial disaggregase CLPB ameliorates Huntington's disease pathology in mice
doi.org
November 1, 2026 at 7:00 AM
The authors included RRIDs in their in Theranostics paper! RRIDs improve reproducibility in scientific research. #OpenScience #STMpublishing #ReproducibleResearch
AIEgen Targets the STAT3‒SUCLG2 Axis to Regulate Metabolism for Colorectal Cancer Theranostics
DOI: https://doi.org/10.1002/agt2.70383
DOI: https://doi.org/10.1002/agt2.70383
October 29, 2026 at 5:31 AM
AIEgen Targets the STAT3‒SUCLG2 Axis to Regulate Metabolism for Colorectal Cancer Theranostics
DOI: https://doi.org/10.1002/agt2.70383
DOI: https://doi.org/10.1002/agt2.70383
RRIDs were included in this in Theranostics paper. We value the author's support of reproducibility. #OpenScience #RRID #STMpublishing
PINK1/Parkin promotes liver regeneration via Sigma-1 ubiquitination to inhibit ER-Mitochondrial calcium transfer
Read the full paper: PINK1/Parkin promotes liver regeneration via Sigma-1 ubiquitination to inhibit ER-Mitochondrial calcium transfer
doi.org
November 1, 2026 at 7:00 AM
RRIDs were included in this in Theranostics paper. We value the author's support of reproducibility. #OpenScience #RRID #STMpublishing
RRIDs were included in this in Chemistry – A European Journal paper. We value the author's support of reproducibility. #reproducibility #OpenScience #BetterScience
A Sequentially Activated Nanoreactor With DNAzyme Cascade for Precise Breast Cancer Theranostics
Read the full paper: A Sequentially Activated Nanoreactor With DNAzyme Cascade for Precise Breast Cancer Theranostics
doi.org
October 30, 2026 at 7:07 AM
RRIDs were included in this in Chemistry – A European Journal paper. We value the author's support of reproducibility. #reproducibility #OpenScience #BetterScience
United Theranostics Welcomes Amber Woodward-Smith as CFO for National Growth Initiative#United_States#CFO#Bethesda#United_Theranostics#Amber_Woodward-Smith
United Theranostics Welcomes Amber Woodward-Smith as CFO for National Growth Initiative
Amber Woodward-Smith has been appointed as the new CFO of United Theranostics, aiming to enhance patient access to advanced cancer therapies across the nation.
third-news.com
October 29, 2026 at 5:24 PM
United Theranostics Welcomes Amber Woodward-Smith as CFO for National Growth Initiative#United_States#CFO#Bethesda#United_Theranostics#Amber_Woodward-Smith
⚠️ $RDPTF Radiopharm Theranostics: Estimated funding runway of only 0.70 quarters, Q1 FY26 operating cash outflow A$10.687M, and cash of A$7.462M—going-concern style disclosures triggered [HIGH RISK]
October 30, 2026 at 2:30 PM
⚠️ $RDPTF Radiopharm Theranostics: Estimated funding runway of only 0.70 quarters, Q1 FY26 operating cash outflow A$10.687M, and cash of A$7.462M—going-concern style disclosures triggered [HIGH RISK]
The authors included RRIDs in their in Theranostics paper! RRIDs improve reproducibility in scientific research. #RRID #methodsmatter #OpenScience
Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesis in vitro and in vivo
Read the full paper: Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesis in vitro and in vivo
doi.org
November 1, 2026 at 7:00 AM
The authors included RRIDs in their in Theranostics paper! RRIDs improve reproducibility in scientific research. #RRID #methodsmatter #OpenScience
Radiographers’ Perceptions of Artificial Intelligence and Theranostics: Implications for Job Security and Professional Adaptation
Artificial Intelligence (AI) and theranostics are transforming radiographic…
📄 PDF: sjoranm.com/sjoranm/article/download/101/89
#SJORANM #Radiology #NuclearMedicine
Artificial Intelligence (AI) and theranostics are transforming radiographic…
📄 PDF: sjoranm.com/sjoranm/article/download/101/89
#SJORANM #Radiology #NuclearMedicine
Radiographers’ Perceptions of Artificial Intelligence and Theranostics: Implications for Job Security and Professional Adaptation
Swiss J. Radiol. Nucl. Med. · Vol. 27 No. 1 · 2026-01-30 · DOI doi.org/10.59667/sjoranm.v27i1.18 · Artificial Intelligence (AI) and theranostics are transforming radiographic practice by enhancing diagnostic precision and enabling personalized treatment. However, these innovations raise concerns…
sjoranm.com
October 29, 2026 at 12:34 AM
Radiographers’ Perceptions of Artificial Intelligence and Theranostics: Implications for Job Security and Professional Adaptation
Artificial Intelligence (AI) and theranostics are transforming radiographic…
📄 PDF: sjoranm.com/sjoranm/article/download/101/89
#SJORANM #Radiology #NuclearMedicine
Artificial Intelligence (AI) and theranostics are transforming radiographic…
📄 PDF: sjoranm.com/sjoranm/article/download/101/89
#SJORANM #Radiology #NuclearMedicine